![]() They wrote that the potential risk for thromboembolic events had to be evaluated before using any potential reversal agent to reverse rivaroxaban-induced bleeding. The researchers found that reversal of rivaroxaban anticoagulant effects ex vivo was possible, but varied between reversal agents and the coagulation assay. The effects of the procoagulant factors on laboratory coagulation parameters were assessed on blood treated ex vivo with rivaroxaban, or blood from patients treated with rivaroxaban. ![]() NEW research testing the efficacy of reversal agents for novel oral anticoagulant (NOAC) rivaroxaban has been inconclusive, highlighting the advantage that dabigatran has over other NOACs, says the Australian expert who headed the trial that led to its approval.Ī recent Austrian study, published in the British Journal of Anaesthesia, tested ex vivo reversal of rivaroxaban with various non-specific reversal agents, namely prothrombin complex concentrate, activated prothrombin complex concentrate, recombinant activated factor VII, and fibrinogen concentrate. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |